Atrial FibrillationNCT04850508
Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation
An observational study of Atrial Fibrillation, run by University of Calgary at 1 site in Canada.
Trial summary
The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Mapping and ablation with the Advisor HD Grid catheter
- Type of treatment
- Medical device
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 27 Sep 2021to 1 Nov 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation.
Who may be able to join
- Patients with symptomatic paroxysmal or persistent atrial Fibrillation.1
- Patients referred for a clinically indicated catheter ablation with a plan for PVI only.
- 18-85 year of age at time of consent.
- Able and willing to comply with all protocol requirements.
- Signed patient Informed Consent (ICF).
Who cannot join
- History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE. Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV-node reentry tachycardia or right-sided focal ectopic atrial tachycardia may be included.
- Planned for left atrial ablation beyond PVI.
- Uncontrolled heart Failure or NYHA Class III or IV heart failure.
- Left ventricular ejection fraction < 35 %
- Left atrial size > 55 mm diameter on echocardiogram.
- Severe Pulmonary Hypertension
Show all 15Show fewer
- Reversible causes of AF (electrolyte imbalance, thyroid disease…)
- Poor candidate for general anesthesia or deep sedation
- Anticipated survival < 1 year
- MI or CABG within 3 months, severe valvular disease
- Any documented thromboembolic event within 6 months.
- Contraindication to systemic oral anticoagulation therapy.
- Significant congenital anomaly or medical condition that may affect the integrity of study data.
- Women who are pregnant or breastfeeding.
- Active enrollment in another investigational study involving a drug or device.
Trial locations and contacts
1 site in 1 country.
About this study
The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. A minimum of 20 evaluable subjects with symptomatic atrial fibrillation scheduled for a clinically indicated first PVI ablation will be included.
Read the detailed description
Background and Rationale:
The main target in atrial fibrillation ablation is the isolation of the pulmonary veins (PVI). This is performed by point-by-point ablation with radiofrequency energy creating 2 circles, one around the left superior and inferior pulmonary vein and one around the right superior and inferior pulmonary vein. The current standard of mapping the pulmonary vein ostia during PVI ablation is a 20-pole circumferential catheter (CMC-20) which collects anatomical and electrical information by moving it in the left atrium and making contact with the atrial wall. Isolation of pulmonary veins is confirmed by other methods such as bidirectional block across the ablation lesions.
New technological developments have resulted in high-density mapping, such as the Advisor HD Grid mapping catheter by Abbott. This catheter has a total of 16 electrodes configured in a 4 by 4 matrix. With each electrical wavefront being decomposed to 2 orthogonal vectors, every direction of a local wavefront should be detected by these configurations and thus overcoming the bipolar blindness.
Research Question and Objectives:
The primary objective of this study is to demonstrate the superiority of the HD Grid catheter when compared to the CMC-20 catheter in atrial fibrillation ablation.
The primary endpoint is the mean number of gaps identified per patient, and their location identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Secondary endpoints are:
- A per vein analysis will be performed for the presence of gaps and for the mean number of gaps.
- A per pair of veins (left and right separately) analysis will be performed for the presence of gaps and for the mean number of gaps.
- Left atrial mapping time for both the CMC-20 and the HD Grid catheter
- Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.
Design:
Prospective, single arm, single center, superiority study with comparison of standard 20-pole circular mapping catheter and the new HD Grid multipolar catheter.
A minimum of 20 evaluable subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation will be enrolled over a period of 12 months.
Data collection:
Demographic, clinical and AF-related information will be collected prior to the procedure. Procedure related information will be collected directly after the procedure. All data will be collected in RedCap.
Procedure:
First, a standard PVI procedure is performed. After completion of the ablation lesions, isolation of the pulmonary veins will be confirmed using the standard CMC-20 catheter. If isolation is confirmed, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The prevalence and location of these gaps will be collected using the map. If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein.
- Conditions
- Atrial Fibrillation
- Being tested
- Mapping and ablation with the Advisor HD Grid catheter
- Keywords
- Ablation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mapping and ablation with the Advisor HD Grid catheterDevice
After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.
If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of gaps
The primary endpoint is the mean number of gaps identified per patient identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Measured: During the ablation procedure.
Location of gaps
The co-primary endpoint is the location of the gaps identified per patient by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Measured: During the ablation procedure.
Secondary outcomes (6)
Per vein analysis for the presence of any gap.
A per vein analysis will be performed for the presence of any gap as a binary outcome.
Measured: During the ablation procedure.
Per vein analysis for the mean number of gaps.
A per vein analysis will be performed for the mean number of gaps.
Measured: During the ablation procedure.
Per pair of veins analysis for the presence of any gap.
A per pair of veins (left and right separately) analysis will be performed for the presence of any gap as a binary outcome.
Measured: During the ablation procedure.
Per pair of veins analysis for the mean number of gaps.
A per pair of veins (left and right separately) analysis will be performed for the mean number of gaps.
Measured: During the ablation procedure.
Mapping time
Left atrial mapping time for both the CMC-20 and the HD Grid catheter
Measured: During the ablation procedure.
Discrepancies
Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.
Measured: During the ablation procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2021
- Study start27 Sep 2021
- Primary completion1 Nov 2022
- Study completion1 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- More trials run by University of CalgaryThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vikas Kuriachan, University of Calgary
- Investigators
- Vikas P Kuriachan, MD, Principal investigator, Libin Cardiovascular Institute of Alberta, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04850508
- Sponsor's protocol ID
- REB20-2140
- Status last verified
- Nov 2022
- First submitted
- 13 Apr 2021
- Last updated
- 15 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Given the small number of patients in the study individual treatments and outcomes maybe looked at.
Publications
Porterfield C, J Gora P, Wystrach A, Rossi P, Rillo M, A Sebag F, Giuggia M, Mantica M, Dorszewski A, Eldadah Z, Volpicelli M, Bottoni N, Jons C, T Hollis Z, Dekker L, Mathew S, Schmitt J, Nilsson K. Confirmation of Pulmonary Vein Isolation with High-Density Mapping: Comparison to Traditional Workflows. J Atr Fibrillation. 2020 Apr 30;12(6):2361. doi: 10.4022/jafib.2361. eCollection 2020 Apr-May.
PubMed 33024494Vandenberk B, Quinn FR, Barmby J, Wilton SB, Kuriachan V. High-density mapping improves detection of conduction gaps after pulmonary vein isolation ablation with a circular mapping catheter. J Interv Card Electrophysiol. 2023 Sep;66(6):1401-1410. doi: 10.1007/s10840-022-01434-3. Epub 2022 Dec 3.
PubMed 36462064
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation
- ClinicalTrials.gov ID
- NCT04850508
- Acronym / sponsor ID
- REB20-2140
- Conditions
- Atrial Fibrillation
- Keywords
- Ablation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Study start
- 27 Sep 2021 (actual)
- Primary completion
- 1 Nov 2022 (actual)
- Study completion
- 1 Nov 2022 (actual)
- First posted
- 20 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. A minimum of 20 evaluable subjects with symptomatic atrial fibrillation scheduled for a clinically indicated first PVI ablation will be included.
Detailed description
Background and Rationale:
The main target in atrial fibrillation ablation is the isolation of the pulmonary veins (PVI). This is performed by point-by-point ablation with radiofrequency energy creating 2 circles, one around the left superior and inferior pulmonary vein and one around the right superior and inferior pulmonary vein. The current standard of mapping the pulmonary vein ostia during PVI ablation is a 20-pole circumferential catheter (CMC-20) which collects anatomical and electrical information by moving it in the left atrium and making contact with the atrial wall. Isolation of pulmonary veins is confirmed by other methods such as bidirectional block across the ablation lesions.
New technological developments have resulted in high-density mapping, such as the Advisor HD Grid mapping catheter by Abbott. This catheter has a total of 16 electrodes configured in a 4 by 4 matrix. With each electrical wavefront being decomposed to 2 orthogonal vectors, every direction of a local wavefront should be detected by these configurations and thus overcoming the bipolar blindness.
Research Question and Objectives:
The primary objective of this study is to demonstrate the superiority of the HD Grid catheter when compared to the CMC-20 catheter in atrial fibrillation ablation.
The primary endpoint is the mean number of gaps identified per patient, and their location identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Secondary endpoints are:
- A per vein analysis will be performed for the presence of gaps and for the mean number of gaps.
- A per pair of veins (left and right separately) analysis will be performed for the presence of gaps and for the mean number of gaps.
- Left atrial mapping time for both the CMC-20 and the HD Grid catheter
- Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.
Design:
Prospective, single arm, single center, superiority study with comparison of standard 20-pole circular mapping catheter and the new HD Grid multipolar catheter.
A minimum of 20 evaluable subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation will be enrolled over a period of 12 months.
Data collection:
Demographic, clinical and AF-related information will be collected prior to the procedure. Procedure related information will be collected directly after the procedure. All data will be collected in RedCap.
Procedure:
First, a standard PVI procedure is performed. After completion of the ablation lesions, isolation of the pulmonary veins will be confirmed using the standard CMC-20 catheter. If isolation is confirmed, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The prevalence and location of these gaps will be collected using the map. If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation.
Key inclusion criteria (5 listed)
- Patients with symptomatic paroxysmal or persistent atrial Fibrillation.1
- Patients referred for a clinically indicated catheter ablation with a plan for PVI only.
- 18-85 year of age at time of consent.
- Able and willing to comply with all protocol requirements.
- Signed patient Informed Consent (ICF).
Key exclusion criteria (15 listed)
- History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE. Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV-node reentry tachycardia or right-sided focal ectopic atrial tachycardia may be included.
- Planned for left atrial ablation beyond PVI.
- Uncontrolled heart Failure or NYHA Class III or IV heart failure.
- Left ventricular ejection fraction < 35 %
- Left atrial size > 55 mm diameter on echocardiogram.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mapping and ablation with the Advisor HD Grid catheterAfter confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side. If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed. | Device | – |
Primary outcome
Number of gaps
Time frame: During the ablation procedure.
The primary endpoint is the mean number of gaps identified per patient identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
Location of gaps
Time frame: During the ablation procedure.
The co-primary endpoint is the location of the gaps identified per patient by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.
6 secondary outcomes
Per vein analysis for the presence of any gap.
Time frame: During the ablation procedure.
Per vein analysis for the mean number of gaps.
Time frame: During the ablation procedure.
Per pair of veins analysis for the presence of any gap.
Time frame: During the ablation procedure.
Per pair of veins analysis for the mean number of gaps.
Time frame: During the ablation procedure.
Mapping time
Time frame: During the ablation procedure.
Discrepancies
Time frame: During the ablation procedure.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2022.
- Background: PubMed 33024494Porterfield C, J Gora P, Wystrach A, Rossi P, Rillo M, A Sebag F, Giuggia M, Mantica M, Dorszewski A, Eldadah Z, Volpicelli M, Bottoni N, Jons C, T Hollis Z, Dekker L, Mathew S, Schmitt J, Nilsson K. Confirmation of Pulmonary Vein Isolation with High-Density Mapping: Comparison to Traditional Workflows. J Atr Fibrillation. 2020 Apr 30;12(6):2361. doi: 10.4022/jafib.2361. eCollection 2020 Apr-May.
- Derived from this study: PubMed 36462064Vandenberk B, Quinn FR, Barmby J, Wilton SB, Kuriachan V. High-density mapping improves detection of conduction gaps after pulmonary vein isolation ablation with a circular mapping catheter. J Interv Card Electrophysiol. 2023 Sep;66(6):1401-1410. doi: 10.1007/s10840-022-01434-3. Epub 2022 Dec 3.
- Individual participant dataSharing planned: No. Given the small number of patients in the study individual treatments and outcomes maybe looked at.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vikas P Kuriachan, MD principal investigator
Libin Cardiovascular Institute of Alberta, University of Calgary
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation, run by University of Calgary at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of gaps (time frame: During the ablation procedure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04850508, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2022.